S96. CARDIOVASCULAR DISEASE RISK IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR DISORDER

• Published in: Schizophrenia bulletin 2018-04, Vol.44 (suppl_1), p.S362-S362
• Main Authors: Rødevand, Linn, Steen, Nils Eiel, Quintana, Daniel, Reponen, Elina Johanna, Mørch, Ragni Helene, Lunding, Synve Hoffart, Iversen, Trude, Lagerberg, Trine V, Melle, Ingrid, Andreassen, Ole A
• Format: Article
• Language: English
• Subjects: Abstracts
• ISSN: 0586-7614; 1745-1701
• DOI: 10.1093/schbul/sby018.883

Abstract Background Patients with schizophrenia and bipolar disorder have markedly reduced life expectancy compared to the general population (15–20 years). A major contributor of excess death is cardiovascular disease (CVD) [1]. During the last decade, there have been several public health campaigns for health promotion and disease prevention, and tobacco legislation has become stricter. These strategies appear to have been effective in improving the health of the general Norwegian population [2]. It is unknown whether the elevated CVD risk in patients with schizophrenia and bipolar disorder has sustained in spite of these health promotion approaches. Here we investigate the development of CVD risk factors in a large representative sample of Norwegian patients with schizophrenia and bipolar disorder between 2002 and 2017. More specifically, we explored whether the CVD risk level was similar in a cohort from 2006 and a second cohort from 2017. Methods Cross sectional analysis was performed among DSM-IV diagnosed patients included from 2002–2005 (cohort 1) and from 2006–2017 (cohort 2), respectively. Cohort 1 consisted of 161 patients with schizophrenia and 109 patients with bipolar disorder, and cohort 2 consisted of 623 patients with schizophrenia and 387 patients with bipolar disorder. Comparisons were made between cohorts regarding demographic variables, psychiatric symptoms, tobacco use, body mass index, waist circumference, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, fasting glucose, systolic blood pressure, and diastolic blood pressure. ANCOVA was used for these analyses, with adjustments for age, duration of the disorder, and duration of psychopharmacological treatment. Results Mean age was significantly higher for cohort 1 (35.1 years vs. 31.2 years, p < .001). There was no statistically significant difference in any of the other demographic variables or symptoms. Among patients with schizophrenia, there was no significant difference in the prevalence of CVD risk factors except from glucose being slightly increased in patients included in cohort 2 (p = .047). Among patients with bipolar disorder, there was a significant reduction in the level of total cholesterol, LDL, systolic, and diastolic blood pressure in cohort 2 (all p values < .01). These differences remained statistically significant after adjusting for age, duration of the disorder, and duration of psychopharmaco